News & Updates

Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
15 Jan 2024
Maintenance olaparib rechallenge improves PFS in ovarian cancer patients
Maintenance olaparib rechallenge improves PFS in ovarian cancer patients
13 Jan 2024 byStephen Padilla

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.

Maintenance olaparib rechallenge improves PFS in ovarian cancer patients
13 Jan 2024
Survivors cope with life after testicular cancer
Survivors cope with life after testicular cancer
13 Jan 2024

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.

Survivors cope with life after testicular cancer
13 Jan 2024
Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women
Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women
11 Jan 2024 byJairia Dela Cruz

Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.

Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women
11 Jan 2024